Daclatasvir and Sofosbuvir Tablets

Key Benefits
- Used for the treatment of chronic hepatitis C infection
- Helps suppress hepatitis C virus replication
- Combines two direct-acting antiviral agents for complementary antiviral activity
- May support sustained virologic response when used as prescribed
- Can be used in appropriate patients with selected HCV genotypes and clinical conditions
How It Works
Sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, an enzyme required for viral RNA replication. Daclatasvir inhibits the HCV NS5A protein, which is important for viral replication and assembly. By targeting these different viral proteins, the combination helps prevent hepatitis C virus from multiplying.
Common Side Effects
- Headache
- Fatigue
- Nausea
- Diarrhea
- Insomnia
- Dizziness
- Weakness
Important Information
Daclatasvir and Sofosbuvir Tablets should be used under the supervision of a qualified healthcare professional experienced in the management of hepatitis C. The appropriate treatment regimen and duration depend on factors such as HCV genotype, liver condition, previous treatment history, and other medicines being used. Tell your doctor about all medicines and supplements you take, as important drug interactions may occur. Patients with advanced liver disease may require additional monitoring. Do not stop or change treatment without medical advice, as incomplete treatment may reduce effectiveness and contribute to antiviral resistance.